Journal article

Mitoxantrone, More than Just Another Topoisomerase II Poison

Benny J Evison, Brad E Sleebs, Keith G Watson, Don R Phillips, Suzanne M Cutts

MEDICINAL RESEARCH REVIEWS | WILEY | Published : 2016

Abstract

Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is commonly applied in the treatment of breast and prostate cancers, lymphomas, and leukemias. A comprehensive overview of the drug's molecular, biochemical, and cellular pharmacology is presented here, beginning with the cardiotoxic nature of its predecessor doxorubicin and how these properties shaped the pharmacology of mitoxantrone itself. Although mitoxantrone is firmly established as a DNA topoisomerase II poison within mammalian cells, it is now clear that the drug interacts with a much broader range of biological macromolecules both covalently and noncovalently..

View full abstract

University of Melbourne Researchers